Novartis' patent on diabetes drug Vildagliptin expires tomorrow, prices to fall by 60%
Updated : December 09, 2019 02:55 PM IST
Vildagliptin is a part of a class of diabetes medications called dipeptidyl peptidase IV or DPP4 inhibitors.
Novartis’ patent on Vildagliptin is expiring on December 9, 2019, and companies can sell its generic version from tomorrow.
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morning
YOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more